Madrigal: A Vertex-Like Outcome Is Plausible — A Long Trade to Own the MASH Story
Madrigal Pharmaceuticals (MDGL) is a commercial-stage liver-focused biotech with an FDA- and EC-approved therapy (Rezdiffra) and a growing combination-ready pipeline. The balance sheet, recent licensing deals and an oversold technical setup create an asymmetric trade: entry at $452.76, stop at $360.00, target $800.00 over a long-term window (180 tr…